BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Yuan Y, Meng L, Fan H, Xu J, Zhang H, Wang M, Yuan H, Ou N, Zhang H, Chao Y, Shi R. Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers. Eur J Clin Pharmacol 2011;67:25-31. [PMID: 21110014 DOI: 10.1007/s00228-010-0949-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Yan Z, Zhang H, Sun L, Jiao H, Wang M, Yu L, Yu L, Yuan Z, Meng L, Wang Y. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects. Eur J Clin Pharmacol 2017;73:547-54. [DOI: 10.1007/s00228-017-2206-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Zhang H, Zhang X, Liu J, Sun L, Shen Y, Zhou C, Zhang H, Xie L, Chen J, Liu Y, Wang Y. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacological Research 2020;152:104606. [DOI: 10.1016/j.phrs.2019.104606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sun LN, Cao Y, Li YQ, Fang YQ, Zhang HW, Wang MF, Xie LJ, Chen J, Yang ZC, Bian ML, Li H, Zhang PP, Wei JF, Meng L, Zhang XH, Zhao P, Wang YQ. Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects. Front Pharmacol 2017;8:670. [PMID: 29018343 DOI: 10.3389/fphar.2017.00670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Yang Y, Zhang Z, Li P, Kong W, Liu X, Liu L. A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators. Pharmaceutics 2021;13:698. [PMID: 34064886 DOI: 10.3390/pharmaceutics13050698] [Reference Citation Analysis]
5 Yu LY, Sun LN, Zhang XH, Li YQ, Yu L, Yuan ZQ, Meng L, Zhang HW, Wang YQ. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Adv Ther. 2017;34:1070-1086. [PMID: 28429247 DOI: 10.1007/s12325-017-0532-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 9.6] [Reference Citation Analysis]
6 Wang Y, Tang N, Meng L, Zhang P, Xu K, Jiang N, Zhang H, Ou N, Wu D, Chen A, Zhang X, Shi R. Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects. Clin Drug Investig 2012;32:247-52. [PMID: 22299715 DOI: 10.2165/11599110-000000000-00000] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Seo KA, Lee SJ, Kim KB, Bae SK, Liu KH, Kim DH, Shin JG. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42:278-284. [PMID: 22022918 DOI: 10.1517/13543776.2013.741121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]